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Sumoylation has recently emerged as a key post-translational modification involved in
many, if not all, biological processes. Small Ubiquitin-like Modifier (SUMO) polypeptides
are covalently attached to specific lysine residues of target proteins through a
dedicated enzymatic pathway. Disruption of the SUMO enzymatic pathway in the
developing brain leads to lethality indicating that this process exerts a central role
during embryonic and post-natal development. However, little is still known regarding
how this highly dynamic protein modification is regulated in the mammalian brain
despite an increasing number of data implicating sumoylated substrates in synapse
formation, synaptic communication and plasticity. The aim of this review is therefore
to briefly describe the enzymatic SUMO pathway and to give an overview of our current
knowledge on the function and dysfunction of protein sumoylation at the mammalian
synapse.
Keywords: synapse, post-translational modification, sumoylation, desumoylation, SUMO
INTRODUCTION
As the mammalian brain develops, crucial sequential processes take place for a functional neuronal
circuitry to be established. These processes are as follows: embryonic neurogenesis that gives
rise to neuronal cells from the progenitors within the neural tube; migration of these newly born
neurons to their destination area that is followed by maturation and formation of interneuronal
connections. The spatiotemporal regulation of these processes, which results in the formation and
the stabilization of synaptic connections, participates in the shaping of a physiologically active
and functional brain circuitry. The formation of a mature functional synaptic contact starts with
an axonal outgrowth until the growth cone reaches a target neuron. The axonal growth cone
transforms into a presynaptic terminal that is characterized by the presence of neurotransmitter-
filled synaptic vesicles and faces the postsynaptic area i.e., the dendritic spine, which is enriched
in neurotransmitter receptors. The functional synapse is capable of integrating an electrical signal
into biochemical changes, a process referred to as synaptic transmission. Importantly, the term
‘‘synaptic plasticity’’ regroups a wide range of molecular mechanisms that allow the modification
of the strength and efficacy of synaptic transmission, and thereby underpin the ability of the brain
to respond to environmental changes and/or experiences, and consequently underlie cognitive
functions.
The molecular composition and organization of a mature synapse is incredibly complex. It has
been estimated that ‘‘an average’’ synapse contains 300,000 proteins (Wilhelm et al., 2014). As
these proteins mediate synaptic transmission and plasticity their interactions must be regulated
both in time and space and this is mostly achieved by posttranslational modifications (PTMs).
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Accordingly, it is widely accepted that most types of plasticity
are expressed through changes in the number of postsynaptic
glutamate receptors and these changes are regulated by PTMs
(for a comprehensive review, see Yokoi et al., 2012). For
instance, both CaMKII and PKC phosphorylation of the GluA1
subunit of AMPA receptors (AMPARs) increase single-channel
conductance of AMPARs leading to expression of long-term
potentiation (LTP) in the hippocampus. In addition, previous
studies have reported that PKC-phosphorylation of the AMPAR
subunit GluA2 regulates its protein-protein interactions in the
cerebellum leading to the expression of an activity-dependent
long-term decrease in synaptic strength known as long-term
depression (LTD; Matsuda et al., 2000). It has also been shown
that the synaptic function can be regulated via other PTMs.
Ubiquitination is a reversible PTM that can direct target proteins
for degradation through the ubiquitin proteasome system
(UPS). Bingol and Schuman (2006) reported that proteasome
constituents and ubiquitin moiety are present in dendrites and
upon neuronal activation the dendritic UPS moves into spines
to shape the synaptic protein composition and subsequently
the synaptic function. Interestingly, sumoylation has recently
emerged as an essential PTM in the central nervous system
(CNS) that profoundly alters protein activity, stability and
subcellular localization, controls protein-protein interactions,
and is important for the brain development and the regulation
of synaptic communication (for recent reviews see Gwizdek et al.,
2013; Henley et al., 2014). Moreover, perturbations in neuronal
sumoylation have been implicated in numerous pathological
conditions (reviewed in Dorval and Fraser, 2007; Martin et al.,
2007b; Martin, 2009; Krumova and Weishaupt, 2012; Lee et al.,
2013; Henley et al., 2014).
THE ENZYMATIC MACHINERY OF SMALL
UBIQUITIN LIKE MODIFIERS
Sumoylation is an evolutionarily conserved enzymatic pathway,
analogous to the ubiquitination process, which covalently and
reversibly conjugates a small protein of ∼100 amino acids,
called Small Ubiquitin-like Modifier(SUMO,∼11 kDa), to lysine
residues of target proteins (Matunis et al., 1996; Mahajan et al.,
1997).
Four SUMO paralogs have been identified in humans until
now. SUMO1–3 are ubiquitously expressed (Hay, 2005; Geiss-
Friedlander and Melchior, 2007) whereas SUMO4 expression
seems restricted to the spleen, the kidney and the lymphatic
nodes (Bohren et al., 2004; Guo et al., 2004). SUMO2 and
SUMO3 are nearly identical except three additional N-terminal
residues within the SUMO3 sequence; therefore they are
generally referred to as SUMO2/3. On the contrary, SUMO1
shares only ∼50% sequence identity with SUMO2/3. SUMO1
and SUMO2/3 modify an overlapping set of target proteins; but
they differ in their properties and subcellular abundance with
the amount of free available SUMO2/3 being much larger that
of SUMO1.
In most cases, the SUMO-targeted lysine resides within
a specific consensus site defined as ψ-K-x-D/E, where
ψ corresponds to a large hydrophobic residue, K stands for
lysine, x is any amino acid, and D/E are glutamate and aspartate
acidic residues respectively (Rodriguez et al., 2001; Sampson
et al., 2001). Importantly, not all consensus sequences are
sumoylated and not all SUMO-target proteins are modified
within this particular motif. Several additional sumoylation
sites were identified, which revealed that the sequences flanking
the target lysine residue are critical to determine whether a
site can be SUMO-modified or not (reviewed in Flotho and
Melchior, 2013; Henley et al., 2014). It is also important to
note that many of the lysine residues contained within SUMO
consensus sites are reported as not sumoylated. However,
in most cases the determination of such sumoylation status
was achieved in basal unstimulated conditions. Therefore,
caution should be taken to definitively state that a given
protein is not a SUMO substrate since only a small proportion
of a specific protein is sumoylated at steady state (Hay,
2005).
The sumoylation/desumoylation cycle (Figure 1) starts with
the cleavage of inactive SUMO precursor proteins by the
hydrolase activity of the SENtrin-specific Protease (SENP,
Mukhopadhyay and Dasso, 2007; Hickey et al., 2012) enzymes
so the C-terminal di-glycine motif on SUMO is uncovered
for conjugation. Mature SUMOs are then activated by the
SAE1 and SAE2 (SUMO-activating enzyme subunit 1 and 2;
also named AoS1/Uba2 in rodents) heterodimer complex in
an ATP-dependent manner. Afterwards, SUMO conjugation to
target substrate proteins is carried out by the sole conjugating
enzyme of the SUMO system, Ubc9 (Figure 1). This conjugation
step can be achieved either directly or in combination with an E3
SUMO ligase (Bernier-Villamor et al., 2002). These E3 proteins
assist the sumoylation step either by bringing the substrate
and the SUMO-Ubc9 in close proximity or by enhancing the
transfer rate of SUMO onto the substrate (reviewed in Gareau
and Lima, 2010; Flotho and Melchior, 2013). In the brain, the
mechanisms, by which these E3 SUMO ligases operate and how
they participate in the SUMO process to enhance sumoylation
in neurons, are still largely unknown. However recent evidence
suggests that these E3 ligases may be extremely important to
tightly regulate the synaptic function.
The sumoylation/desumylation cycle (Figure 1) is highly
dynamic andmust be tightly controlled as it drastically influences
the function of many proteins targeted by this PTM. Despite a
covalent SUMO binding, sumoylation is a reversible process due
to the isopeptidase activity of specific enzymes (see Hickey et al.,
2012, for a comprehensive review on SUMO proteases). The
desumoylation enzymes allow the removal of the SUMOmoieties
from modified substrates leaving non-sumoylated proteins and
matured SUMOs available to re-enter the SUMO pathway.
Several SUMO proteases effectively mediate this desumoylation
process. In humans, six SENP proteases have been described
(SENP1, 2, 3, 5, 6 and 7). These desumoylation enzymes differ
in their subcellular localization and SUMO selectivity (Hickey
et al., 2012). Recently, several additional SUMO proteases
have been identified, DeSumoylating Isopeptidase 1 and 2
(DeSI1 and DeSI2; Shin et al., 2012) and USPL1 (Ubiquitin-
Specific Protease-Like 1; Schulz et al., 2012). These SUMO
proteases together with the SUMO-conjugating pathway convey
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FIGURE 1 | The SUMO enzymatic pathway. SUMO paralogs are synthesized as inactive precursors that are first matured by the hydrolase activity of specific
desumoylases called SENPs. SUMO activation is an ATP-dependent step leading to formation of a thioester bond between the SUMO-activating subunit SAE2 of
the E1 enzymatic heterodimer SAE1/SAE2 and the activated SUMO. SUMO is then transferred onto the active (C93) cysteine residue of Ubc9, the sole
E2-conjugating enzyme of the SUMO system. Ubc9 is able to catalyze the sumoylation reaction of the target lysine residue on the substrate either directly or in
combination with one of the existing SUMO E3 ligases. Importantly, sumoylation is readily reversible and sumoylated proteins can be efficiently desumoylated via the
isopeptidase activity of a variety of SUMO proteases including SENPs, DeSI1/2 and/or USPL1.
an essential role to allow the dynamic equilibrium between the
sumoylated and desumoylated state of many proteins. Since
sumoylation participates in the regulation of many proteins
involved in essential developmental processes and synaptic
functions, dysregulation of the sumoylation/desumoylation
balance may directly link the SUMO process to a number of
pathophysiological conditions (see thereafter, ‘‘Sumoylation in
Synaptopathies’’ Section).
SUMOYLATION IN BRAIN DEVELOPMENT,
NEURONAL MATURATION AND SYNAPSE
FORMATION
Sumoylation in Brain Development
Sumoylation acts throughout the neuronal cell to dynamically
modulate protein function and consequently SUMO enzymatic
machinery members present a widespread subcellular
distribution including the nucleus (Martin et al., 2007a;
Loriol et al., 2012; Wang et al., 2012; Hasegawa et al., 2014),
the mitochondrial surface (Guo et al., 2013), the dendritic shaft
and both pre- and postsynaptic elements (Martin et al., 2007a;
Feligioni et al., 2009; Loriol et al., 2012, 2013, 2014; Gwizdek
et al., 2013; Luo et al., 2013; Hasegawa et al., 2014).
To date, three separate studies have examined the
spatiotemporal distribution of the sumoylation machinery
members in the developing rodent brain with consistent results
(Watanabe et al., 2008; Loriol et al., 2012; Hasegawa et al.,
2014). The expression levels of both Ubc9 and SUMO1 mRNA
are developmentally regulated in the rat brain, with higher
expression levels before birth (Watanabe et al., 2008). Only
recently, we reported that the protein expression levels of
sumoylated proteins, the SUMO-activation enzyme SAE1, the
SUMO-conjugating Ubc9 and the two desumoylation enzymes
SENP1 and SENP6 are developmentally regulated in the rat
brain (Loriol et al., 2012). SUMO1/2/3-conjugated protein
levels are at their maximum at embryonic day 12, followed by
a slow decrease until birth. SUMO1-modified protein levels
progressively decrease until the adult stage. However, a second
increasing phase occurs for SUMO2/3-ylated substrates just
after birth. Interestingly, while the overall sumoylation slowly
decreases after birth reaching relatively low levels in the adult
brain, there are progressively more SUMO substrates within
synaptic compartments (Loriol et al., 2012). The relative
accumulation in synaptic SUMO substrates in aged rat brain
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is also consistent with an enrichment of the sumoylation
enzymes AoS1 and Ubc9 in dendritic spines of fully mature rat
neurons.
More recently, Hasegawa et al. (2014) combined
immunohistochemical and immunoblot analyses on mouse
brain at various developmental stages and also showed
a developmental distribution of all SUMO moieties and
the SUMO-conjugating enzyme Ubc9. During embryonic
development, sumoylation occurred in the nucleoplasm of
nestin-positive neural stem cells. Although the total amount
of SUMO-modified proteins decreased during postnatal
mouse brain development similar to the developing rat brain
(Loriol et al., 2012), a persistent accumulation of SUMO2/3
was detected in neural progenitor populations in neurogenic
regions throughout life (Hasegawa et al., 2014). In addition,
a strong SUMO1-immunoreactivity was observed in large
projection neurons in the brainstem suggesting that SUMO1-
and SUMO2/3-modified proteins exert specific functions in the
mouse brain.
The abundance and distribution of the sumoylation
machinery play a critical role during embryonic and postnatal
development. For instance, it was previously thought that
SUMO2 and SUMO3 paralogs act in a totally redundant
manner. Wang et al. (2014) recently revealed that SUMO2
is the predominantly expressed isoform in early embryonic
stages of mouse development. Indeed, SUMO3-KO mice
are viable while SUMO2 deficiency in mice leads to severe
developmental delay and embryonic lethality, which strongly
suggests that the spatiotemporal expression of these SUMO
moieties, and not their functional differences (the two paralogs
being almost identical), is a critical factor during the brain
development.
Fu et al. (2014) investigated the role of SENP2 in the brain
development by engineering a mouse model that expressed
SUMO-protease activity-deficient SENP2 in neural progenitors.
The authors showed that SENP2 is indispensable for the
brain development. Indeed, SENP2 loss of function evoked
an increase in neuronal sumoylation levels eventually leading
to a robust post-natal neurodegeneration resulting in paralysis
and death of the mice by three weeks of age (Fu et al.,
2014). They also demonstrated that this neurodegeneration is
the consequence of the hyper-sumoylation of Drp1 (Dynamin-
related protein 1), which promoted its enhanced association
with mitochondria and their subsequent fragmentation leading
to neuronal apoptosis. Altogether, these data confirmed the
importance of a controlled balance between the sumoylation
and desumoylation state of a protein in the developing
brain.
Sumoylation in Neuronal Maturation and
Synapse Formation
We have reported, that the sumoylation enzymes AoS1, Ubc9
as well as the SUMO proteases SENP1 and SENP6 were
differentially redistributed in pre- and postsynaptic areas during
neuronal maturation (Loriol et al., 2012). We further showed
that the redistribution of the sumoylation machinery in and out
of synapses is also observed upon neuronal depolarization and
that this enzymatic redistribution impacts the synaptic levels of
sumoylation (Loriol et al., 2013). Altogether, these data suggested
that the SUMO process and the involved SUMO targets are
not only important for the brain development but also for
the maturation of neuronal cells and consequently for synaptic
function.
MeCP2 (Methyl CpG Binding Protein 2)
Hundreds of mutations within the MeCP2 gene, which is located
on the X-chromosome, have been linked to neurodevelopmental
disorders, most frequently to Rett syndrome in females but also
to some forms of autism, and schizophrenia. The Rett syndrome
is behaviorally characterized by a developmental stagnation in
early childhood associated with severe cognitive impairment and
autistic features, the loss of spoken language and hand use. The
encoded MeCP2 protein is a DNA-binding protein expressed
ubiquitously and acts as a transcriptional repressor that fulfils
key roles during the synaptic development (Guerrini and Parrini,
2012). Sumoylation of MeCP2 regulates its interaction with the
transcriptional repression complex HDAC1/2 and preventing
sumoylation in MeCP2 at the K223 residue leads to abnormal
gene expression and impaired synaptic density (Cheng et al.,
2014).
More recently, Tai et al. (2016) reported that MeCP2 is
modified on different lysine residues e.g., K353 and K412,
but failed to detect the K223 sumoylation. They showed
that phosphorylation is required for MeCP2 sumoylation
and that the SUMO E3 ligase PIAS actively participates
in MeCP2 modification. They also elegantly demonstrated
that MeCP2 sumoylation in the hippocampus is induced
by several factors including the activation of NMDA
receptors (NMDARs), the Insulin-like growth factor (IGF-1)
and the Corticotropin-Releasing Factor (CRF) revealing a
previously unsuspected activity-dependent regulation of MeCP2
sumoylation. Importantly, preventing MeCP2 sumoylation
using the non-sumoylatable K412R MeCP2 mutant leads to
a decrease in its DNA binding ability whereas a MeCP2-
SUMO1 fusion significantly increases its DNA binding
capabilities (Tai et al., 2016). Altogether, these data reinforce
the idea that MeCP2 sumoylation is essential to its function
and acts as a central regulator of MeCP2 function in the
brain.
MEF2 Proteins (Myocyte-Enhancer Factor 2)
The establishment of functional synaptic circuits relies on the
concomitant activity-dependent formation and elimination of
synapses. MEF2 members form a family of four evolutionarily
conserved transcriptional factors (MEF2A, B, C and D) that
were first identified in muscle differentiation. They are also
expressed throughout the brain including areas involved in
cognitive functions (cortex, hippocampus, amygdala, striatum;
reviewed in Rashid et al., 2014). Mutations within MEF2 genes
have been directly linked to various pathological conditions
including epilepsies, autism, and some neurodegenerative
disorders (Flavell and Greenberg, 2008; Li et al., 2008; Yin
et al., 2012) suggesting that these brain diseases could be
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triggered by abnormal MEF2-dependent gene transcription
programs. Notably, MEF2 s are involved in several important
neurodevelopmental processes including cell differentiation,
dendritic morphogenesis, synapse formation, pruning and
synaptic plasticity.
MEF2 activities are regulated through several PTMs including
acetylation (Grégoire and Yang, 2005; Shalizi et al., 2007),
phosphorylation (Flavell et al., 2006; Kang et al., 2006)
and sumoylation (Grégoire and Yang, 2005; Zhao et al.,
2005; Shalizi et al., 2006, 2007; Lu et al., 2013). A decade
ago, Shalizi et al. (2006) investigated the SUMO-dependent
repression of MEF2A in the developing cerebellar cortex.
They demonstrated that there is an activity-dependent switch
from a sumoylated MEF2A at the lysine 403 to its acetylated
state leading to MEF2A activation and inhibition of dendritic
claw differentiation and consequently to synapse disassembly
(Shalizi et al., 2006). They used overexpression and knockdown
strategies to show that PIASx is a MEF2 SUMO-E3 ligase linking
this E3 protein to postsynaptic dendritic claw morphogenesis
in the cerebellar cortex and confirming the essential role
of protein sumoylation in the developing brain (Shalizi
et al., 2007). MEF2A was also reported to be sumoylated
both in vitro and in vivo at the lysine 395 residue and
the E3 SUMO ligase PIAS1 enhances its sumoylation and
subsequently decreases its transcriptional activity (Riquelme
et al., 2006).
More recently, the Bonni’s group reported that MEF2A
sumoylation participates in presynaptic differentiation in the
rat brain (Yamada et al., 2013). Indeed, while the in vivo
knockdown of MEF2A in the rat cerebellar cortex increases
the density of orphan presynaptic sites, the sumoylated
transcriptional repressor form of MEF2A drives the suppression
of these sites via the direct repression of the gene encoding
the presynaptic protein Synaptotagmin 1 (Yamada et al.,
2013).
Lu et al. (2013) have engineered SENP2 knockout
embryos and used in vivo SUMO assays to demonstrate
that SENP2, but not SENP1, is the MEF2A desumoylating
enzyme. They also showed via co-expression of SENP2
and MEF2A with a luciferase reporter gene a SENP2-
dependent increase in MEF2A transcriptional activity (Lu
et al., 2013) further highlighting the importance of the
SUMO process in the transcriptional regulation mediated
by MEF2A.
MEF2C, another member of the MEF2 family, is also a
sumoylation substrate (Kang et al., 2006). Sumoylation at
K391 repressed MEF2C transcriptional activity without altering
its DNA-binding properties. Interestingly, phosphorylation at
S396 in MEF2C, five residues downstream of the sumoylation
site, potentiated MEF2C sumoylation (Kang et al., 2006).
The phospho-deficient S396A mutant of MEF2C showed a
reduced sumoylation in vivo with the concurrent increase in its
transcriptional activity further confirming that the regulation
of MEF2 activities is controlled by the crosstalk between
phosphorylation and sumoylation.
The last member of the MEF2 family to be reported a
SUMO substrate is MEF2D. MEF2D sumoylation occurs at
the lysine 439 residue (Grégoire and Yang, 2005). The authors
showed that the K439 SUMO2/3-ylation of MEF2D strongly
decreases its transcriptional activity. In agreement with this,
they demonstrated that SENP3 activity is able to increase the
transcriptional activity of MEF2D by lowering its sumoylation
(Grégoire and Yang, 2005). The same group reported that the
kinase Cdk5 promotes MEF2D phosphorylation at the serine 444
residue leading to an increased sumoylation of the protein and
consequently to the inhibition of the transcriptional activity of
MEF2D (Grégoire et al., 2006). Altogether, these data indicate
that the transcriptional activity of MEF2 proteins is tightly
regulated through the interplay between several PTMs, e.g.,
phosphorylation, acetylation and sumoylation, to tightly control
the developmental expression of essential target genes involved
in brain development and plasticity.
FOXP2 (Forkhead Box Protein P2)
FOXP2 belongs to the forkhead box (FOX) family of
transcription factors. Disruption of the FOXP2 gene has
been implicated in a rare and severe form of autosomal-
dominant language and speech disorder (Lai et al., 2001).
This disorder was first described in a British family (known
as the KE family), in which half of their members struggle
to develop coordinated orofacial movements. These patients
also express incomprehensive written and spoken language,
but they do not show any cognitive impairment. All the
affected family members carry the missense arginine to
histidine mutation at position 553 (R553H) in FOXP2,
which abolishes its DNA binding and consequently fails to
repress transcription of many target genes (Lai et al., 2001).
FOXP2 is mainly expressed during neuronal differentiation
in many brain areas including the cortex, basal ganglia,
thalamus and hippocampus (Lai et al., 2003). Importantly,
FOXP2 regulates expression of genes that are important for
neuronal development and synaptogenesis. For instance,
FOXP2 regulates the expression of DISC1 that is involved
in neurogenesis, synapse regulation, neuronal outgrowth,
migration, differentiation and proliferation (reviewed in
Brandon and Sawa, 2011).
Only recently, three independent studies reported that
FOXP2 is sumoylated in vitro and in vivo by all SUMO
paralogs predominantly at the lysine 674 residue (Estruch et al.,
2016; Meredith et al., 2016; Usui et al., 2016). They further
showed that FOXP2 interacts with the E3 SUMO ligases PIAS1
and PIAS3 promoting FOXP2 sumoylation (Estruch et al.,
2016; Usui et al., 2016) whereas SENP2 activity significantly
decreases its sumoylation (Usui et al., 2016). The FOXP2-
PIAS1/3 interaction leads to redistribution of FOXP2 to the
nuclear speckles. Interestingly, abolition of the sumoylation
site via the K674R mutation did not cause any changes in
FOXP2 stability, transcriptional repression or dimerization
with the WT sumoylatable form of FOXP2. The subcellular
localization of FOXP2 K674R mutant was reported both in
vitro and in vivo to be increased in the cytoplasm and
decreased in the nucleus (Usui et al., 2016). Importantly, the
human etiological FOXP2 R553H mutation led to a dramatic
decrease in the ability of FOXP2 R553H to be sumoylated
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(Meredith et al., 2016). They further showed that the pathogenic
R553H mutation negatively influences the interaction between
FOXP2 and the PIAS ligases (Estruch et al., 2016; Meredith et al.,
2016).
The cerebellum harbors important motor coordination
and speech functions and the expression of FOXP2 in the
cerebellum is restricted to Purkinje cells (PC). Usui et al.
(2016) have reported that FOXP2 sumoylation is increased
during neuronal differentiation in the cerebellum suggesting
a key role for sumoylation in cerebellar development.
They further showed using mouse neural progenitor cells
that overexpression of the WT form of FOXP2 results in
long neurites expressing either the immature neuronal
marker Tuj1 or the mature neuronal marker MAP2.
Interestingly, the overexpression of the SUMO-deficient
K674R FOXP2 mutant failed to promote elongation of
Tuj1- and MAP2-positive neurites as effectively as the WT
FOXP2 indicating that FOXP2 sumoylation is essential to
neuronal maturation. In utero electroporation to knockdown
FOXP2 expression in the cerebellum led to a dramatic
reduction in dendritic outgrowth and arborization of
PC (Usui et al., 2016). This reduction was rescued by
re-expression of the WT sumoylatable form of FOXP2 but
not its sumoylation-deficient K674R mutant. Strikingly,
the impairments in cerebellum-based motor behaviors
such as righting reflex or negative geotaxis observed in
FOXP2 knockdown mice were rescued with the expression
of the WT form of FOXP2, but not with its sumoylation-
deficient K674R mutant confirming the essential role of
FOXP2 sumoylation in the developing cerebellum (Usui et al.,
2016).
A knock-in mouse model expressing the pathogenic R552H
FOXP2 mutation (corresponding to the human FOXP2 R553H
mutation) exhibited an immature development of the cerebellum
with impaired neuronal migration and autism-related deficits
such as decreased ultrasonic vocalizations (Fujita et al., 2008).
These vocalization defects were rescued by introducing the
WT form of FOXP2 but not its sumoylation-deficient mutant
(Usui et al., 2016) further demonstrating that impaired
FOXP2 sumoylation could participate in the etiology of
FOXP2-related developmental verbal/vocal communication in
mammals.
CASK (Calcium/Calmodulin-Dependent Serine
Protein Kinase)
CASK is a member of the membrane-associated guanylate
kinase (MAGUK) protein family. MAGUK proteins have
scaffolding properties and interact with many proteins involved
in spinogenesis. CASK expression is high in the mammalian
brain and extremely critical as its genetic deletion in mice
causes neonatal lethality. Mutations within the CASK gene on
the X-chromosome have been identified in human patients
presenting severe neurological defects, microcephaly and mental
impairments, highlighting an essential role of the CASK protein
during the brain development (Hsueh, 2009; Hackett et al.,
2010).
At the molecular level, CASK binds to a myriad of proteins
important for embryonic development, synapse formation and
plasticity (Hsueh, 2006). For instance, CASK interacts with
the adhesion molecules, e.g., neurexin and syndecans, with
cytoplasmic adaptor proteins such as Mint1, SAP97 and CIP98,
and with calcium channel proteins. CASK also participates in the
regulation of synaptic transmission via its indirect interaction
with vesicles that transport the NMDAR subunit NR2B to
the plasma membrane (Huang and Hsueh, 2009; Setou et al.,
2000).
CASK functions as a multidomain scaffolding protein and
has been shown to be sumoylated on the lysine 679 residue
(Chao et al., 2008). The sumoylation of CASK reduces the
interaction between CASK and the protein 4.1. Mammalian
4.1 proteins are known to act as hubs for cytoskeleton-
membrane protein organization and cellular signaling. Notably,
protein 4.1 connects spectrin to the actin cytoskeleton and
this interaction is crucial for spinogenesis (Huang and Hsueh,
2009). Therefore, in order to evaluate the role of CASK
sumoylation in spinogenesis, the authors fused SUMO1 to CASK
and overexpressed this chimearic construct in hippocampal
neurons. They showed a dramatic impairment in spine
number and size (Chao et al., 2008) indicating that CASK
sumoylation is essential for spinogenesis. Interestingly, CASK
is also expressed presynaptically and future research could
therefore shed light on the role of CASK sumoylation in
synaptic vesicles (SVs) trafficking and/or neurotransmitter
release.
PRESYNAPTIC SUMOYLATION
The main function of the presynaptic terminal is to
orchestrate the release of neurotransmitter from SVs upon
neuronal depolarization (reviewed in Südhof and Rizo, 2011;
Südhof, 2013). This essential activity-dependent process
requires a tightly controlled spatiotemporal regulation
of protein-protein interactions between a myriad of
molecules to achieve the calcium-dependent fusion of
SVs with the presynaptic membrane and the subsequent
release of the neurotransmitter in the synaptic cleft.
These dynamic events are mostly regulated via PTMs and
sumoylation is clearly emerging as a key process at the
presynapse.
Feligioni et al. (2009) used a modified synaptosomal
preparation protocol to trap exogenous conjugatable SUMO1
polypeptides or the catalytically active domain of the
desumoylation enzyme SENP1 in synaptosomes to respectively
increase or decrease the presynaptic sumoylation levels and
measure the impact of sumoylation on glutamate release.
They reported that the increase in presynaptic sumoylation
reduced Ca2+ influx and decreased glutamate release upon
KCl depolarization. In contrast, decreasing presynaptic
sumoylation by introducing SENP1 into synaptosomes
led to an enhanced Ca2+ influx and glutamate release in
KCl-stimulated conditions (Feligioni et al., 2009). This
study was the first to provide evidence for a direct role
of the SUMO process at the presynapse via modulation
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FIGURE 2 | Regulation of the presynaptic function by sumoylation. Consistent with the emerging presynaptic functions of sumoylation, its enzymatic
machinery is localized at the presynapse and several presynaptic proteins are SUMO subtrates. (A) Transport of mRNAs along axons is a key mechanism to
dynamically control the function of proteins in growth cones. The axonal mRNA-binding protein La is a SUMO substrate. La is transported toward the end of the
axon by its association to kinesins while sumoylated La proteins are bound to dyneins and therefore undergo retrograde transport toward the soma. (B) Presynaptic
sumoylation emerges as a central protein modification acting at several stages of the neurotransmitter release mechanism. (1) Sumoylation of Synapsin Ia (SynIa)
potentiates its association with synaptic vesicles and thus participates in the clustering of these vesicles at the presynapse. (2) Synaptotagmin-1 is sumoylated in
vivo but the precise function of this modification is still not known. (3) Syntaxin-1A sumoylation is evoked upon NMDA receptor (NMDAR) activation leading to a
decreased binding to SNAP-25 and VAMP-2 and thus acting as a key presynaptic regulator of vesicle endocytosis. (4) RIM1α sumoylation is required for presynaptic
exocytosis since depolarization-evoked vesicle exocytosis with a non-sumoylatable RIM1α mutant is dramatically impaired. This effect is mainly due to a defect in
presynaptic calcium entry following neuronal activation since RIM1α sumoylation enables the binding to Cav2.1 calcium channels and coordinates the presynaptic
Ca2+ entry. (5) CRMP2 is a SUMO substrate and dynamically reduces Ca2+ entry through the presynaptic voltage-gated Ca2+ channel CaV2.2. CRMP2
sumoylation is also believed to regulate the membrane expression of the sodium channel NaV1.7. (6) mGluR7 is sumoylatable both in vitro but also in vivo in rat
hippocampal and cortical neurons. mGluR7 agonist activation triggers the endocytosis of the WT mGluR7 but not the internalization of its non-sumoylatable mutant
suggesting that sumoylation acts on the endocytic pathway. However, overexpressing the desumoylase SENP1 increases the pool of internalized mGluR7, which
rather implies that mGluR7 sumoylation is important for recycling of these receptors back to the plasma membrane and not for the receptor endocytosis per se.
(7) Activation of CB1 receptors in rat cortical neurons increases the overall SUMO1 conjugation. CB1 receptors are potentially sumoylated in resting cells but not in
CB1 receptor-activated conditions. However, the confirmation that these receptors are sumoylated at presynaptic sites and whether the SUMO modification impacts
presynaptic endocannabinoid functions are still not determined. (8) Kv potassium channels play critical roles in neuronal excitability and sumoylation of a number
of these channels (Kv1.1, Kv2.1, Kv7.2, Kv7.3) have been reported to act as molecular regulators of their intrinsic activity. Question marks in red indicate that the
physiological consequences of the target protein sumoylation are still not clearly defined.
of calcium influx and glutamate release but the molecular
pathway and presynaptic proteins targeted by this PTMs
were not described at that time. Since then, several key
axonal and presynaptic proteins have been reported to be
the target of the SUMO system and a better view about
the complexity of this process as well as the functional
role of sumoylation at the presynapse is now emerging
(Figure 2).
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La Protein
The human La protein was originally identified as an auto-
antigen in an immune system disorder called Sjogren’s
syndrome. Levels of circulating anti-La autoantibodies are
used for the diagnosis of this autoimmune syndrome but
also in cases of systemic lupus erythematosus and neonatal
lupus syndrome. La is the smallest member (46kDa) but
the most abundant of the La-related protein (LARP) family
(reviewed in Stavraka and Blagden, 2015). Its particular LAM
motif adopts a special conformation commonly seen in DNA
transcription factors and its RNA-interacting motif RRM allows
the binding, protection and axonal transport of many mRNAs.
However, how the expression and function of La are regulated
remains largely unexplored. To date, it has been shown that
phosphorylation of La regulates its activity and possibly its
ability to recognize mRNAs. Two kinases, CK2 and Akt,
have been so far identified to phosporylate the La protein
(Broekhuis et al., 2000; Brenet et al., 2009; Bayfield et al.,
2010). Furthermore, (van Niekerk et al., 2007) reported that
La is a SUMO substrate and that sumoylated La binds to
dynein allowing its retrograde axonal transport. Conversely, the
native non-sumoylated La interacts with kinesin and undergoes
anterograde axonal transport (Figure 2A). This pioneer study
showed that sumoylation is a key regulatory mechanism for
transporting mRNAs towards their local translation sites, which
represents a crucial process for the maintenance of the axonal
and growth cone pool of proteins that are required for synaptic
transmission.
Kv Channels (Voltage-Gated Potassium Ion
Channels)
Kv channels form potassium-selective pores that span through
the plasma membrane and are essential for the generation
of action potentials and the control of neuronal excitability.
Mutations in subunits forming some of these channels have
been implicated in epilepsies and sudden unexplained death
in epilepsy (SUDEP). Investigations into the regulatory roles
of sumoylation on potassium channel activities have revealed
exciting features. However, most of these works were not
achieved in neurons since Kv channels also regulate the
excitability of many non-neuronal cells (recently reviewed in
Wu et al., 2016). Hereafter, we describe the functional effects
of sumoylation of voltage-gated potassium channels in the
CNS.
Potassium Kv1.1 channels are abundantly expressed in the
brain and localize in large axons where they form tetramers
with Kv1.2 subunits. These channels regulate action potential
propagation, neuronal firing and neurotransmitter release
(Dodson and Forsythe, 2004). Mutations within the human gene
encoding Kv1.1 have been associated with partial epilepsy and
episodic ataxia in humans (Zuberi et al., 1999). Knock-in mice
with Kv1.1 mutations also exhibit hippocampal hyperexcitability,
severe epilepsy and premature death (Glasscock et al., 2007).
Qi et al. (2014) engineered a post-natal deficient SENP2
mouse model that develops spontaneous seizures and sudden
death. They also reported that the SENP2 deficiency results in
increased levels of sumoylation for several potassium channels
known to impact neuronal excitability including the Kv1.1
that is modified by both SUMO1/2 and colocalizes with
SENP2 in hippocampal neurons. However, the sumoylation
of Kv1.1 did not significantly affect its channel properties
and activity. Interestingly, the authors have also reported in
this work that the Kv7.2 is hyper-sumoylated by SUMO2/3
in hippocampal neurons. Kv7 potassium channels play critical
roles in neuronal excitability. Two Kv7 members, Kv7.2
and Kv7.3, are highly expressed in neurons and generate
the M-current that is important for firing action potentials.
Strikingly, the hyper-sumoylation of Kv7.2 resulted in a
significant decrease in the depolarizing M-current in SENP2-
deficient hippocampal CA3 neurons and consequently led
to neuronal hyperexcitability, severe seizures and ultimately,
to sudden death of mice by a maximum of 8 weeks of
age (Qi et al., 2014). These symptoms were prevented by
administration of an approved anti-epileptic drug retigabine.
This effective drug acts as a specific Kv7.2 opener and counteracts
neuronal hyperexcitability. However, how this drug impacts the
sumoylation levels of Kv7.2/7.3 in hippocampal neurons has not
been investigated.
Voltage-gated Kv2.1 channels have also been shown to
be the target of the SUMO system. While sumoylation of
these channels was initially demonstrated in native pancreatic
cells where it regulates beta-cell excitability (Dai et al.,
2009), Plant et al. (2011) reported a functional role of
Kv2.1 sumoylation in hippocampal neurons. Kv2.1 potassium
channels are important in neurons for determining the activity-
dependent excitability. They reported that sumoylation occurs
at the lysine 470 residue and showed that two Kv2.1 subunits
have to be modified within a functional Kv2.1 tetramer to
produce full SUMO response. Kv2.1 sumoylation led to a
35 mV shift in the half-maximal activation voltage of the
functional channel, which resulted in its increased sensitivity
to depolarization (Plant et al., 2011). Therefore, sumoylation
of Kv2.1 channels provides a way to directly control neuronal
excitability.
Synapsin Ia
Synapsins are synaptic proteins essential for the establishment,
clustering and release of presynaptic vesicles (Cesca et al., 2010).
Synapsin Ia (SynIa) is involved in maintaining the reverse pool of
synaptic vesicles that is required when neuronal stimulation lasts
for longer period of time. Tang et al. (2015) demonstrated that
SynIa is sumoylated at the K687 residue and this sumoylation
potentiates its association with synaptic vesicles participating
in the clustering and anchoring of these vesicles into the
presynaptic element (Figure 2B). The lysine-687 to arginine
mutation resulted in complete absence of SynIa sumoylation,
decrease in the number of releasable synaptic vesicles and
impaired exocytosis (Tang et al., 2015). Notably, the A548T
mutation in SynIa that co-segregates with autism also impairs
SynIa sumoylation. Defects in SynIa sumoylation may therefore
be involved in the pathophysiology of neurological disorders
through a SUMO-dependent deregulation of SynIa function at
the presynapse. Altogether, sumoylation of SynIa appears to be
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critical for the activity-dependent release of neurotransmitter
and may therefore actively participate in synaptic transmission
and potentially in long-term synaptic plasticity events.
Syntaxin-1A
The activity-dependent exocytosis of neurotransmitters at
presynaptic sites and the subsequent recycling of synaptic vesicles
are essential processes underlying synaptic communication. The
exocytotic event is mediated through the action of the SNARE
(Soluble N-ethylmaleimide sensitive factor Attachment protein
REceptor) protein complex that includes the 35 kDa-membrane
protein Syntaxin-1A (Stx1A), SNAP-25 and VAMP-2, and
additional proteins such as Munc18, Synaptotagmins and
RIM1α (Figure 2B). Stx1A has been reported to be important
in neuronal survival (Kofuji et al., 2014), neurotransmitter
release and recycling of SV (Watanabe et al., 2013). The
role of Stx1A in neurotransmitter release is also supported
by studies reporting a possible involvement of Stx1A in the
pathophysiology of autism with Stx1A mRNA expression levels
being significantly higher in autistic patients compared to
controls (Nakamura et al., 2008). Furthermore, the STX1A
gene, which is located at the chromosome 7q11.23, has been
found duplicated in patients with speech delay and autism
spectrum behaviors (Berg et al., 2007; Depienne et al., 2007).
All these findings therefore converge to the idea that Stx1A
is critically important for synapse formation, presynaptic
function and neuronal transmission in the developing
brain.
Interestingly, Stx1A has been recently reported as a novel
presynaptic sumoylation target (Craig et al., 2015). Stx1A
sumoylation is evoked upon NMDAR activation or following
KCl-depolarization in hippocampal neurons. This activity-
dependent sumoylation occurs at three lysine sites (K252, 253,
256) and reduces Stx1A binding to SNAP-25 and VAMP-2,
but not to Munc18a. Importantly, neuronal expression of a
non-sumoylatable form of Stx1A via the mutation of the three
SUMO sites into arginine residues, leads to a significant increase
in presynaptic vesicle endocytosis (Craig et al., 2015). This
suggests that Stx1A sumoylation is critically involved in the
maintenance of the balance between SV endocytosis/exocytosis
and subsequently in neurotransmitter release. However, how
exactly the sumoylated form of Stx1A enhances SV endocytosis
as well as how Stx1A desumoylation occurs in this context has
not yet been investigated.
Synaptotagmin-1
Membrane fusion is a key mechanism occurring for many
processes including protein/lipid transport, hormone and
neurotransmitter release. Membrane fusion at presynaptic
site involves not only the SNARE proteins but also several
other presynaptic factors to orchestrate neurotransmission
in a timely dependent way (reviewed in Südhof and Rizo,
2011; Südhof, 2013). Among these are calcium sensor proteins
called synaptotagmins. To date, 16 isoforms of synaptotagmins
have been identified in mammals that either colocalize with
synaptic/secretory vesicles or are distributed at the plasma
membrane. Although not directly related to presynaptic
exocytotic function, Dai et al. (2011) reported that SENP1
overexpression enhances insulin exocytosis in pancreatic β-cells
via the association of SUMO1 to Synaptotagmin VII. More
interesting is the presynaptic function of Synaptotagmin-1
(Syt1) sumoylation. Syt1 is well known to exert important
roles at the presynapse to sense the calcium influx that
arises through the activated voltage-gated calcium channels
and thus Syt1 participates in neurotransmitter release
(Figure 2B).
To assess the role of sumoylation in neuronal function,
the Fraser lab used a proteomic approach on transgenic mice
that exclusively over-expressed the human form of SUMO1
in neurons (Matsuzaki et al., 2015). The effect of this over-
expression was a simultaneous increase in the level of non-
conjugated SUMO1 proteins and in the proportion of high
molecular weight SUMO1-modified targets in transgenic brains
compared to WT brains. The levels of protein expression of
the SUMO enzymes as well as the free fraction of SUMO2/3
proteins in transgenic brain remained similar to those measured
inWT animals. Using mass spectrometry, the authors confirmed
that many of these SUMO1 targets were neuron and synapse-
specific. Importantly, the authors described the sumoylation
of Syt1 and showed that Syt1 sumoylation was upregulated
in these transgenic mice (Matsuzaki et al., 2015). Using field
potential recording in acute hippocampal slices from SUMO1-
transgenic brains, they reported a deficit in basal transmission
suggesting a decrease in synaptic activity and/or a loss of
functional synapses. They also showed that a form of short-
term synaptic plasticity dependent on presynaptic mechanisms,
named paired pulse facilitation, is impaired in SUMO1-
transgenic brain slices, which suggests that SUMO1 over-
expression leads to defects in functional presynaptic mechanisms
(Matsuzaki et al., 2015). They further showed that SUMO1-
over-expressing hippocampal cells exhibit a dramatic loss of
dendritic spines that leads to impairment in contextual fear
memory (Matsuzaki et al., 2015). While the over-expression
of SUMO1 in neurons leads tomultiple alterations, the functional
and physiological functions of Syt1 sumoylation are yet to be
described. Clearly, the hyper-sumoylation observed for Syt1 in
SUMO1-transgenic mice cannot be taken as the unique cause to
explain all the physiological deficits reported in these animals.
However, this work confirmed the importance of a controlled
equilibrium between sumoylation and desumoylation since a
small and uncompensated increase in neuronal sumoylation
directly impacts synaptic architecture, cell communication and
memory formation.
RIM1α (Rab3-Interacting Molecule 1α)
Among the proteins of the presynaptic active zone that have been
extensively studied are the RIM protein family. RIMs interact
either directly or indirectly with several presynaptic proteins
including Rab3a, synapsin-1, Syt1A, Munc13–1, and the voltage-
gated Ca2+ channels (Calakos et al., 2004). These scaffolding
proteins are crucial to the active zone function and consequently
to synaptic transmission (Figure 2B). Specifically, RIM1α has
been implicated in the docking/priming of synaptic vesicles
but also in short and long-term synaptic plasticity (Castillo
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et al., 2002; Dulubova et al., 2005). It is now generally believed
that RIM1α plays key roles in diverse presynaptic functions,
however, the regulatory mechanisms at the presynaptic site
have not been fully elucidated. A recent study from the
Henley lab reported that RIM1α is a SUMO substrate (Girach
et al., 2013). They showed that RIM1α sumoylation occurs
only on the lysine 502 residue independently of the neuronal
activity. Using molecular replacement experiments, they have
substituted the endogenous RIM1α in hippocampal neurons
by the non-sumoylatable RIM1α-K502R mutant. While the
presynaptic localization of both the WT and non-sumoylatable
exogenous RIM1α remained unchanged, there was a marked
decrease in the depolarization-evoked SV exocytosis with the
K502R mutant indicating that RIM1α sumoylation is required
for presynaptic exocytosis (Girach et al., 2013). They further
demonstrated that the outcome measurements of the mutant
were due to a defect in calcium entry following depolarization
since RIM1α sumoylation enables the clustering of Cav2.1
calcium channels. Altogether, (Girach et al., 2013) uncovered
an additional important presynaptic function for the SUMO
process. As there are other isoforms of RIM proteins that are
involved in modulation of presynaptic functions, it would be of
interest to investigate whether and how sumoylation can impact
on these proteins.
CRMP2 (Collapsin Response Mediator
Protein 2)
CRMP2 is a microtubule-binding protein that was originally
identified for its roles in regulation of axonal guidance in
neuronal polarity and more recently, in presynaptic functions
including axonal transport and neurotransmitter release (for
a recent review on CRMP2 see Ip et al., 2014). CRMP2
dynamically interacts with the presynaptic N-type voltage-
gated Ca2+ channel (CaV2.2) and disruption of this complex
reduces pain in a rodent model of neuropathic pain. Thus,
investigation into CRMP2 mechanisms of action is of interest
to understand its role in pain and identify potential therapeutic
targets (Brittain et al., 2011). CRMP2 has been reported to be
sumoylated in vitro on the lysine 374 residue and preventing
CRMP2 sumoylation did not impair its ability to promote
neurite outgrowth (Ju et al., 2013). Using calcium imaging on
primary rat cultures of dorsal root ganglion (DRG) neurons,
the authors showed that the non-sumoylated form of CRMP2
differentially affects the calcium influx in depolarized DRGs
when compared to WT CRMP2 expression suggesting that
CRMP2 sumoylation acts as a negative modulator of presynaptic
calcium influx.
The same group later confirmed that both the WT
and the SUMO-deficient CRMP2 are robustly expressed in
catecholaminergic cells (CAD) and are able to promote neurite
outgrowth in rat DRG neurons (Dustrude et al., 2013).
They have also reported that the sodium channel NaV1.7
is regulated by CRMP2 sumoylation. Preventing sumoylation
by over-expressing SENP1 and SENP2 enzymes in WT
CRMP2-expressing CAD cells decreased the NaV1.7 currents.
Accordingly, there was a significant decrease in the levels of
surface-expressed NaV1.7 in CAD cells expressing the SUMO-
deficient form of CRMP2. NaV1.7 currents were also decreased
in sensory neurons expressing the non-sumoylatable CRMP2
K374A mutant (Dustrude et al., 2013).
Overall these two reports highlight the putative function of
CRMP2 sumoylation in the regulation of calcium and sodium
channels; however, the authors did not demonstrate CRMP2
sumoylation in vivo. It is also to be determined whether
CRMP2 sumoylation directly modifies the activity or the surface
expression of the two channels. Further work will therefore be
required to clarify the functional role of CRMP2 sumoylation at
presynaptic sites.
Metabotropic Glutamate Receptors
Metabotropic glutamate receptors (mGluRs) form a family
of G-protein coupled receptors that are centrally involved in
excitatory neurotransmission and synaptic plasticity. mGluRs
are divided into three groups based on their sequence
homology, G-protein coupling and ligand specificity (reviewed in
Niswender and Conn, 2010). The group III consists of mGluR4,
6, 7 and 8, and is of particular interest since these receptors
typically exert presynaptic inhibitory functions. In the past years,
several group III mGluRs have been shown to be sumoylated
mainly in vitro but also in vivo, however until recently, there was
no compelling evidence regarding the functional roles for such
modifications (Tang et al., 2005; Wilkinson et al., 2008; Dütting
et al., 2011; Wilkinson and Henley, 2011).
The functional role of sumoylation in mGluRs has been
so far addressed solely for the mGluR7. These receptors
are widely expressed presynaptically and modulate excitatory
neurotransmission as well as synaptic plasticity by inhibiting
neurotransmitter release (reviewed in Niswender and Conn,
2010). C-terminal truncated forms of mGluR7 were found
to be sumoylated at the K889 residue in vitro (Wilkinson
et al., 2008; Wilkinson and Henley, 2011). In a recent study,
Choi et al. (2016) confirmed that mGluR7 is a SUMO
substrate in vitro. They have also shown that these receptors
are sumoylated in vivo in both the rat hippocampus and
primary cortical neurons with the mGluR7-K889 residue
identified as the sole sumoylation site. While mGluR7 can
be sumoylated by both SUMO1 and SUMO2/3 in HEK293T
cells, only SUMO1 conjugation was reported in hippocampal
homogenates (Choi et al., 2016). Since the sumoylation process
has been directly involved in the endocytosis of glutamate
receptors in hippocampal neurons (Martin et al., 2007a),
the authors investigated whether sumoylation has an effect
on mGluR7 internalization (Figure 2B). Constitutive agonist-
independent endocytosis of the non-sumoylatable mGluR7
K889R mutant was increased compared to the WT control
receptor. Addition of L-AP4 mGluR7 agonist to the cells
expressing WT receptors triggers the endocytosis of mGluR7.
This increase in agonist-evoked mGluR7 endocytosis was not
seen for the non-sumoylatable mGluR7. The authors attributed
this lack of effect to the sumoylation process directly acting
on the endocytic pathway. However, they cannot rule out that
sumoylation rather impact on the recycling properties of the
pathway. It is indeed likely that sumoylation acts after the
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endocytosis of mGluR7 by preventing the recycling of the non-
sumoylatable receptor. This is in line with their data showing
that overexpression of SENP1, which prevents sumoylation,
leads to an increase in the internalized population of WT
mGluR7 similar to the values measured for the endocytosed
population of the non-sumoylatable mutant in the absence of
SENP1. This could be explained by a decrease in the SUMO-
dependent recycling of internalized mGluR7 to the plasma
membrane that leads to an increased intracellular pool of
receptors. Since this pathway was not assessed, it is difficult
to conclude about the exact role of mGluR7 sumoylation in
the internalization/recycling process. Furthermore, mGluR7s
are primarily expressed at presynaptic sites (Niswender and
Conn, 2010). Since the current work (Choi et al., 2016)
examined the postsynaptic endocytic properties of an over-
expressed tagged version mGluR7, it implies that further work
will now be necessary to assess the functional impact of mGluR7
sumoylation at presynaptic sites and whether this SUMO
modification influences neuronal excitability and/or synaptic
transmission and plasticity.
Cannabinoid Receptor 1
The endocannabinoid system fulfils complex neuromodulatory
functions in brain development and synaptic plasticity (reviewed
in Lu and Mackie, 2016). It is composed of endogenous
cannabinoid substrates (endocannabinoids), receptors and
enzymes that synthesize and degrade endocannabinoids.
Strikingly, impairments of the endocannabinoid system have
been implicated in several psychiatric disorders. The most
abundant endocannabinoid receptors, CB1 and CB2, belong
to the family of G-protein coupled receptors, which primarily
couple to G proteins of the Gi and Go classes. Their activation
leads to inhibition of adenylyl cyclases and modulation of
presynaptic voltage-dependent calcium channels as well as
certain potassium channels (Lu and Mackie, 2016). CB1 and
CB2 receptors are involved in a number of physiological
functions, such as gene transcription, cell motility and synaptic
communication. CB1 receptors are highly expressed in the
cortex, basal ganglia, hippocampus, and the cerebellum.
CB1 receptors are primarily present at presynaptic terminals
(Figure 2B) while CB2 receptors, which are expressed at
a much lower level in the CNS, are mainly expressed in
microglia and vascular elements. Activation of CB1 receptors
in rat cortical neurons leads to an increase in the overall
SUMO1 conjugation as well as an increase in the levels of free
SUMO1 (Gowran et al., 2009). The authors further showed
that CB1 receptors were potentially sumoylated in basal but
not in CB1 receptor-activated conditions (Gowran et al.,
2009). However, there have been no reports so far regarding
which CB1 receptor residues are sumoylated and whether the
SUMO modification regulates presynaptic endocannabinoid
functions.
In recent years, a lot of work has been achieved
regarding the identification of presynaptic SUMO target
proteins and the function of sumoylation at the presynapse,
placing the SUMO pathway as a key regulator of
protein-protein interactions within this highly crowded
environment. Despite these efforts it is still unknown
how is this timely dependent sumoylation/desumoylation
process orchestrated and future work will be required
to decipher how the targeting, the trafficking and the
activity of the sumoylation and desumoylation enzymes are
regulated in an activity-dependent manner at presynaptic
sites.
POSTSYNAPTIC SUMOYLATION
Spines are small protrusions on dendritic membranes receiving
inputs from axonal termini. Dendritic spines represent the
postsynaptic elements that consist in a head connected to the
dendritic shaft by a narrow neck and contain multiple synaptic
actors, which interact in a coordinated manner to allow synaptic
communication. The first demonstration that sumoylation
acts directly within the synapse has been provided in 2007
with the immunodetection of many unidentified sumoylated
substrates in rat hippocampal PSD95-positive synaptic fractions
as well as with the immunolocalization of the sole SUMO
conjugating enzyme Ubc9 at postsynaptic sites (Martin et al.,
2007a). This work has also identified and characterized the first
synaptic sumoylated substrate i.e., the kainate receptor (KAR)
subunit GluK2, and therefore has opened new avenues for
investigation of the sumoylation process in the brain (Martin
et al., 2007a).
Kainate Receptors
Kainate receptors are ionotropic glutamate receptors that are
functionally active as tetramers composed of the subunits
GluK1–5 (formerly named GluR5–7, KA1 and KA2). KARs
play important roles for synaptic transmission as well as
neuronal excitability (Contractor et al., 2011). They are
expressed at many synapses both pre- and postsynaptically
but also extrasynaptically, where they regulate neuronal
excitability. At the presynapse, they participate in the release
of neurotransmitters, whereas postsynaptically they contribute
to synaptic transmission. The GluK2 subunit directly interacts
with the conjugating enzyme Ubc9 and is a sumoylation
substrate in rat hippocampal neurons (Martin et al., 2007a).
GluK2 sumoylation by SUMO1 occurs in an activity-dependent
manner on its C-terminal domain at the single lysine 886
residue. Since this report, several additional studies have
confirmed the SUMO state of GluK2 in neurons (Konopacki
et al., 2011; Zhu et al., 2012; Choi et al., 2016). Agonist
activation causes the endocytosis of GluK2 receptors via a PKC-
dependent pathway (Martin and Henley, 2004). Interestingly,
the binding of glutamate or kainate to GluK2 leads to its
sumoylation at the plasma membrane and represents a trigger
for the activated receptors to be internalized. Interestingly,
postsynaptic KAR responses at hippocampal mossy fiber-
CA3 synapses decrease when postsynaptic sumoylation is
promoted by infusing SUMO1 postsynaptically and conversely,
postsynaptic responses largely increase in desumoylation
conditions using infusion of the catalytic domain of SENP1
(Martin et al., 2007a). Consistent with earlier publication
(Martin and Henley, 2004), PKC activation has been shown
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to be essential to GluK2 internalization (Konopacki et al.,
2011; Chamberlain et al., 2012). PKC phosphorylation at the
serine 868 in GluK2 is a prerequisite for its sumoylation and
subsequent endocytosis (Konopacki et al., 2011; Chamberlain
et al., 2012).
Arc (Activity-Regulated
Cytoskeleton-Associated
Protein/Activity-Regulated Gene 3.1)
The immediate early gene Arc is capable of coupling changes
in neuronal activity to synaptic plasticity events in a tightly
regulated way (reviewed in Bramham et al., 2010). Arc is a
unique gene required for consolidation of synaptic plasticity
and LTP. Transcription of Arc gene is strongly induced by
synaptic activity. Arc mRNAs are rapidly transported into
dendrites where they undergo local translation at synaptic
sites. Therefore it is not surprising that Arc exhibits key roles
in protein synthesis-dependent forms of synaptic plasticity
and in consolidating different forms of memory (Bramham
et al., 2010). Interestingly, Arc levels are also controlled by
ubiquitination and proteasomal degradation as it was shown that
defective Arc ubiquitination increases Arc levels leading to the
concurrent decrease in synaptic AMPAR receptors (Greer et al.,
2010).
AMPAR are heterotetrameric (GluA1-A4) glutamate-gated
ion channels that underpin the vast majority of fast excitatory
glutamate neurotransmission in the CNS. Interestingly, a chronic
abolishment of neuronal activity promotes AMPARs membrane
expression and in contrast an increase in neuronal activity leads
to decreased surface AMPARs. However, the mechanisms, by
which the number and composition of AMPARs change, are still
not fully understood. To date, it is believed that Arc participates
in the internalization of AMPAR from the plasma membrane
through its interaction with the endocytic endophilin-3 and
dynamin-2 proteins (Chowdhury et al., 2006).
The Henley group reported that Arc is a sumoylation
substrate with the lysine 110 and 268 residues being the sites
of sumoylation (Craig et al., 2012). They also showed that
the suppression of network activity with the sodium channel
blocker tetrodotoxin (TTX) induces SENP1 degradation leading
to the concurrent increase in SUMO1- and SUMO2/3-modified
protein levels in rat cortical neurons in primary culture (Craig
et al., 2012). The level of Arc proteins was dramatically reduced
in TTX conditions independently of its sumoylatable ability
indicating that sumoylation does not exert any stabilizing effect
on Arc. The prolonged exposure to TTX also directly increases
the membrane expression of GluA1 subunits of AMPARs, a
process named synaptic scaling (Turrigiano, 2008). This effect
in surface-expressed AMPAR in TTX condition was prevented
when the catalytic domain of SENP1 was expressed, revealing the
involvement of the SUMO process in this homeostatic scaling
effect (Craig et al., 2012). However, how the SUMO process
participates in the regulation of AMPAR levels at the plasma
membrane, how Arc sumoylation levels are modulated by the
TTX treatment and how Arc sumoylation impacts on AMPAR
trafficking still remain open questions.
Regulation of the Sumoylation Pathway at
the Postsynapse
Despite numerous publications demonstrating the postsynaptic
involvement of sumoylation, it is only recently that some of
the mechanisms regulating this post-translational system at the
post synapse were reported (Loriol et al., 2014; Figure 3). Indeed,
using a combination of pharmacological tools with synaptic
biochemistry and restricted photobleaching/photoconversion of
individual hippocampal spines, our group demonstrated that
the synaptic diffusion of Ubc9, the sole conjugating enzyme
of the sumoylation pathway, is regulated by synaptic activity
on a rapid timescale. The synapto-dendritic diffusion of Ubc9
remained unchanged upon the activation of NMDARs but was
altered through the activation of group I metabotropic mGluR5
receptors (see Niswender and Conn, 2010 for a comprehensive
review on mGluRs signaling pathways). Increasing synaptic
activity with a GABAA receptor antagonist or directly activating
mGlu5R increases the synaptic residency time of Ubc9 in a
PKA-independent but PKC-dependent manner. This transient
synaptic diffusional trapping of Ubc9 enhanced its recognition
to synaptic PKC-phosphorylated substrates and consequently
leads to the increase in synaptic sumoylation (Loriol et al.,
2014; Figure 3). However, despite this first demonstration that
the sumoylation pathway is activity-dependently regulated at
postsynaptic sites, future work will now be required to identify
the nature of these synaptic mGlu5R-activated SUMO substrates
to further decipher the synaptic functions of sumoylation.
Altogether, the data from the above sections clearly establish
that the sumoylation machinery is partly targeted to, localized
and regulated at pre- and postsynaptic sites to modulate in an
activity-dependent manner the levels of synaptic sumoylation
and in turn, the synaptic function. Furthermore, a growing
number of SUMO substrates were recently identified in axons,
dendrites and synapses and shown to fulfil essential physiological
functions on synaptic communication and plasticity (Shalizi
et al., 2006, 2007; Martin et al., 2007a; Chao et al., 2008;
Konopacki et al., 2011; Chamberlain et al., 2012; Craig et al.,
2012, 2015; Girach et al., 2013; Jaafari et al., 2013; Loriol et al.,
2013, 2014; Tang et al., 2015; Tai et al., 2016) revealing the
sumoylation process as an essential modulator of the synaptic
function. Strikingly however, a study combining the use of
a double-tagged His-HA-SUMO1 knock-in mouse model and
mass spectrometry analysis failed to detect any synaptic SUMO
substrates nor any colocalization between His-HA-SUMO1 at
synapses (Tirard et al., 2012). The explanation for these rather
stark differences is still unclear but the authors demonstrated
that the levels of SUMO conjugation decreased in the knock-
in model compared to WT animal suggesting that the dual
SUMO tag partly impairs the sumoylation process. The direct
outcome of this observation is that the synaptic sumoylation
levels may become too low and below the detection sensitivity
of their analysis method. Despite these data, an increasing
number of exciting studies from independent groups worldwide
including ours is now available demonstrating that sumoylation
takes place in neurons and at synapses to regulate synaptic
communication.
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FIGURE 3 | Postsynaptic regulation of the SUMO pathway. The diffusion of Ubc9, the sole conjugating enzyme of the SUMO system is regulated by synaptic
activity. Neuronal activation increases the residency time of the SUMO-conjugationg enzyme Ubc9 at the post-synapse. This synaptic regulation is independent of
NMDAR activation but involves an mGlu5R-dependent signaling pathway that leads to PKC activation. The effect of this activity-dependent PKC phosphorylation is
the increased anchoring of Ubc9 to synaptic phosphorylated protein substrates, which ultimately enhances sumoylation at synapses. Activation of mGlu5R therefore
promotes a transient diffusional trapping of Ubc9 in activated spines via a PKC-dependent pathway, which in turn contributes in the regulation of neuronal excitability.
SUMOYLATION IN SYNAPTIC PLASTICITY
Synaptic plasticity is characterized by the ability of a synapse to
change in strength over long periods of time and this process
is now widely accepted as the cellular model of learning and
memory. Sumoylation, as described above, is centrally involved
in the fine-tuning of neuronal excitability and the regulation of
several pre- and postsynaptic proteins important for synaptic
transmission. In recent years, several pieces of evidence have
accumulated implicating the sumoylation process in plasticity
events.
Phosphorylation of the cAMP-responsive element binding
protein (CREB) at the serine 133 residue via different signaling
cascades, e.g., Ras/ERK, Akt kinase, calcium/calmoduin-
dependent kinases II and IV, protein kinase A, regulates
memory formation and neuronal survival during development
and leads to transcription of genes required for activity-
dependent brain plasticity, which makes CREB a prototypic
transcriptional factor of cognitive function of the brain (Cohen
and Greenberg, 2008; Bell et al., 2013). In an in-depth study
published recently, Chen et al. (2014) investigated the role of
CREB sumoylation and its interplay with phosphorylation
in the rat hippocampal CA1 region. They showed that
CREB sumoylation is enhanced in the presence of PIAS1,
and NMDA injection in the CA1 region increases CREB
sumoylation. Moreover, the spatial training in rats increases
CREB phosphorylation after 1 day of training. After 2 and 5
days the phospho-CREB levels remained unchanged compared
to untrained control animals, whereas CREB sumoylation
increased significantly suggesting a molecular regulatory
switch between phosphorylation and sumoylation during this
learning process. In addition, CREB sumoylation enhanced
the transcription of growth factor Brain-Derived Neurotrophic
Factor (BDNF). Transduction of CREB-SUMO1 fusion vector
to the rat CA1 region increased spatial learning and memory,
whereas PIAS1 knock-down decreased CREB sumoylation
and impaired spatial learning and memory (Chen et al.,
2014). Importantly, the authors provided evidence that
preventing CREB phosphorylation completely abolishes
CREB sumoylation, however preventing CREB sumoylation
on two most prominent sumoylation sites increases CREB
phosphorylation in the CA1 region. Clearly, there is a regulatory
interplay between these two modifications and it will be
of interest to examine whether deregulation of the CREB
phosphorylation/sumoylation crosstalk is relevant in cognitive
disorders.
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LTP (Long-Term Potentiation)
LTP is characterized by a long-lasting increase in synaptic
strength that involves in most cases an activity-dependent
increase in the functionality and the number of postsynaptic
AMPAR (Kneussel and Hausrat, 2016).
Jaafari et al. (2013) applied a chemically-induced LTP assay
(Chem-LTP) on cultured rat hippocampal neurons to investigate
the role of sumoylation in AMPARs surface expression.
This pharmacological approach was previously reported to
significantly increase the surface level of AMPARs (Lu et al.,
2001). Chem-LTP led to an increase in dendritic and synaptic
SUMO1 immunoreactivity as well as a large increase in Ubc9 and
SUMO1 mRNAs in soma and dendrites. Interestingly, the over-
expression of a catalytically active domain of the desumoylase
SENP1, but not its catalytically inactive mutant, prevented the
increase in SUMO1 mRNA and in surface expressed AMPAR
upon Chem-LTP (Jaafari et al., 2013). These results are in favor
of an active role of the sumoylation process in the control of
AMPAR surface expression during LTP. However, the precise
mechanism by which the SUMO process acts on AMPAR surface
expression is still not clear.
The prion-like Cytoplasmic Polyadenylation Element-
Binding protein 3 (CPEB3) regulates the translation of several
mRNAs involved in synaptic plasticity (Pavlopoulos et al.,
2011; Fioriti et al., 2015). Previous studies reported that CPEB
exists as a soluble inactive or insoluble aggregate-prone active
protein (Si et al., 2010), both of which localize at the synapse
(Drisaldi et al., 2015). When aggregated, active CPEB3 can
initiate the translation of specific target mRNAs such as
those coding for the AMPAR subunits GluA1 and GluA2
(Pavlopoulos et al., 2011; Fioriti et al., 2015). Interestingly,
sumoylation of CPEB3 by SUMO2 was shown to regulate
its oligomerization capacity and neuronal activity-dependent
translation of target mRNAs (Drisaldi et al., 2015). In basal state
CPEB3 is sumoylated and acts as a translation repressor. In
vitro and in vivo stimulation of hippocampal neurons triggered
CPEB3 desumoylation leading to its aggregation and mRNA
translation. The authors found that the uncleavable SUMO2-
CPEB3 construct is soluble compared to the non-sumoylated
CPEB3 and showed a decreased ability to aggregate leading to
inhibition of mRNA translation. Stimulation of hippocampal
neurons with glycine led to an increase in the number of
filopodia (immature spines), which was not observed when
neurons expressed SUMO2-CPEB3 (Drisaldi et al., 2015).
Importantly, CPEB3 was reported to induce SUMO2 mRNA
translation upon glycine stimulation. These data suggest that
the SUMO process operates as a regulatory loop influencing the
translation activity of CPEB3, which in turn modulates the levels
of SUMO2 mRNA.
The sumoylation process is required for the expression of
LTP (Lee et al., 2014). Indeed, by combining the use of WT
or catalytically inactive forms of the cell permeable TAT-Ubc9
and LTP protocols in acute CA1 hippocampal slices, the authors
showed that LTP is significantly reduced when sumoylation is
prevented by the dominant negative Ubc9 mutant (Lee et al.,
2014). This LTP inhibition was observed without any impact
on basal transmission. Lee et al. (2014) confirmed their initial
results using the catalytic domain of the desumoylase SENP1
in the patch pipette as used previously (Martin et al., 2007a).
They showed that inclusion of the active SENP1, but not its
catalytically inactive mutant, fully blocked the induction of LTP
in CA1 pyramidal neurons confirming that the SUMO pathway
is involved in the expression of long-term plasticity events (Lee
et al., 2014). They subsequently demonstrated that infusion
of the dominant negative form of TAT-Ubc9 in vivo impairs
the hippocampal-dependent learning and memory (Lee et al.,
2014).
More recently, several MeCP2 gene mutations in patients
with Rett syndrome patients were shown to decrease
MeCP2 sumoylation (Tai et al., 2016). The authors also
demonstrated that the re-expression of the WT form of
MeCP2 in CA1 hippocampal neurons rescued the deficits of
social interaction and the CA1-LTP impairment observed
in MeCP2 conditional knockout mice. Interestingly,
re-expression of the non-sumoylatable K412R form of
MeCP2 in these conditional knockout mice was not able
to rescue the LTP in CA1 hippocampal neurons with
measured values similar to those obtained in MeCP2 KO
animals (Tai et al., 2016). Altogether, these data reveal a
crucial role of MeCP2 sumoylation in social interaction
and synaptic plasticity, and suggest that erratic MeCP2
sumoylation may directly participate in the etiology of Rett
syndrome.
LTD (Long-Term Depression)
LTD is a ubiquitous form of activity-dependent long-lasting
reduction of synaptic strength characterized by a decrease
in the surface expression of neurotransmitter receptors that
often results from the remodeling of their intracellular protein-
interacting partners via PTMs.
As depicted above, the agonist-dependent sumoylation of the
GluK2 subunit at the lysine 886 leads to the internalization of the
sumoylated KAR complexes (Martin et al., 2007a). This process
requires a PKC-phosphorylation of the GluK2 C-terminus at
the serine 868 residue prior to its sumoylation (Konopacki
et al., 2011). Interestingly, it was also reported that both the
PKC-phosphorylation of the serine 868 and the subsequent
sumoylation are required for the internalization of KARs that
occurs during LTD of KAR-mediated synaptic transmission
at rat hippocampal mossy fiber synapses (Chamberlain et al.,
2012). Thus, this work revealed that the interplay between
phosphorylation and sumoylation of GluK2 is important for
activity-dependent KAR synaptic plasticity.
SUMOYLATION IN SYNAPTOPATHIES
The human synaptic proteome is composed of hundreds of
different proteins in many copies and mutations in the encoding
genes lead to more than hundred brain disorders (reviewed
in van Spronsen and Hoogenraad, 2010; Grant, 2012). Spine
architecture, synaptic proteome and neuronal functions are
strongly correlated features, which is never more apparent
than in pathological conditions. Notably, synaptopathies
that are characterized by alterations in spine morphology,
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TABLE 1 | Sumoylation in synaptopathies.
Synaptopathy Implicated Effects Reference
SUMO targets
and machinery
Down syndrome, Trisomy 21 SUMO3 SUMO3 gene is localized on Hsa21. Gardiner (2006)
SUMO3 overdose leads to imbalanced/deregulated
sumoylation.
Parkinson’s disease α-Synuclein Sumoylated by SUMO1 and SUMO2/3.
Involved in protein aggregation.
Kim et al. (2011), Krumova et al. (2011),
and Kunadt et al. (2015)
Another pathogenic mechanism could include
inter-neuronal spreading of α-Syn.
DJ-1 PD mutation disrupts DJ-1 sumoylation and decreases
its solubility.
Shinbo et al. (2006)
Parkin Increase in its E3 Ubiquitin ligase activity by non-covalent
SUMO1 modification.
Um and Chung (2006)
Parkin also associates with and targets the SUMO E3
ligase RanBP2 for degradation. Direct implication with
PD is still lacking.
Huntington’s disease Huntingtin Sumoylation may act as a prevention mechanism for
huntingtin accumulation.
Steffan et al. (2004) and O’Rourke et al.
(2013)
Alzheimer’s disease SAE2, Ubc9, SENP3 Single Nucleotide Polymorphisms in these genes
co-segregate with AD.
Grupe et al. (2007), Weeraratna
et al. (2007), Ahn et al. (2009), and
Corneveaux et al. (2010)
Aβ Unclear results about whether sumoylation of Aβ
enhances or decreases its aggregation.
Li et al. (2003), Dorval et al. (2007), and
Zhang and Sarge (2008)
Tau Proportion between sumoylated and ubiquitinylated Tau
can regulate its degradation/accumulation.
Dorval and Fraser (2006) and Luo et al.
(2014)
Hyper-phosphorylated Tau is immunoreactive
for SUMO1.
synapse number and synaptic function are increasingly seen
as central feature in major psychiatric, brain developmental
and neurodegenerative diseases. These diseases constitute a
major social and economic burden in our societies and it is
therefore essential to gain a better insight into the underlying
molecular and cellular mechanisms prior to developing
effective diagnostic, preventative and eventually therapeutic
strategies.
Since the sumoylation pathway is emerging as a critical
regulator of neuronal and synaptic function under normal
conditions, it is not surprising to see more andmore publications
reporting defective sumoylation events in wide range of brain
disorders. In this section, we review the current knowledge
regarding the multiple sumoylation anomalies reported in
synaptopathies (Table 1).
Down Syndrome (DS)
The DS or trisomy 21, is caused by an extra copy of all
or parts of the long arm of the human chromosome 21
(Hsa21) and is the most common chromosomal abnormality
with about 1:1000 births worldwide (Loane et al., 2013).
Clinical features are multiple with mild to severe intellectual
disabilities, learning defects in short- and long-term memory
formation, typical craniofacial appearance, hypotonia and
premature aging (Perluigi and Butterfield, 2012). On the
neuroanatomical side, DS patients show reduction in brain
size and weight, as well as a decrease in neuronal density
associated with synaptic abnormalities (Kaufmann and Moser,
2000).
DS is believed to result from a gene dosage imbalance leading
to the increased expression of normal chromosome 21 genes.
Accordingly, the overexpression of specific genes located in the
long arm of Hsa21, such as DS Critical Region 1 (DSCR1), the
Amyloid-beta Precursor Protein (APP) and the dual-specificity
tyrosine (Y)-phosphorylation regulated kinase 1A (DYRK1A)
genes have been reported in DS patients (Antonarakis et al., 2004;
Shukkur et al., 2006). However, several studies have also shown
that individual loci were not responsible on their own for specific
anatomical and functional features of DS (Roper and Reeves,
2006; Shukkur et al., 2006).
Interestingly, the SUMO3 gene is located on the long arm
of the Hsa21 and it was reported that there is an increase in
SUMO3-modified proteins in the human hippocampus of post-
mortem DS patient (Gardiner, 2006). This increase in SUMO3-
sumoylation impacts a large number of target proteins that may
include important molecular pathways involved in the synaptic
function and disruption of their sumoylation/desumoylation
balance may explain at least in part, some of the synaptic defect
observed in the patients. Therefore it would be of great interest
to identify and functionally characterize the increased SUMO3
target proteins in DS to evaluate whether this imbalanced
sumoylation may account for some of the reported DS
features.
Parkinson’s Disease (PD)
PD is a neurodegenerative condition caused by impairments of
striatal dopaminergic neurotransmission, and ultimately leads
to gradual loss of dopaminergic neurons in the substantia
Frontiers in Synaptic Neuroscience | www.frontiersin.org 15 April 2016 | Volume 8 | Article 9
Schorova and Martin Synaptic Sumoylation
nigra. Loss of these neuronal projections toward the striatum
is directly correlated with the symptoms of the disease as the
striatal structure is responsible for the control of voluntary
movements. Accordingly, PD patients show significant decline
in motor and non-motor functions, which are symptomatically
expressed as resting tremor, muscle rigidness, impaired balance
as well as speech and writing difficulties. Only 5% of the
PD patients are diagnosed with genetic form of PD and
the etiology of PD is yet to be fully elucidated. A cellular
hallmark of the disease is the formation of intraneuronal
inclusions known as Lewy bodies (LBs) that are often positive
for SUMO1, ubiquitin and α-synuclein (for a recent review,
see Vijayakumaran et al., 2015), therefore linking the SUMO
pathway to the disease.
Sumoylation of α-Synuclein (αSYN)
The major component of LBs is αSYN, a small protein of
14 kDa encoded by the SNCA gene on chromosome 4. About
18 mutations in this gene have been directly linked to familial
forms of PD and generally associate with the early-onset form of
the disease, which typically appears before the age of 50.
The physiological functions of αSYN are still not clearly
established but the protein is mainly localized at presynaptic sites
where it is believed to regulate neurotransmitter release via its
direct association to SNARE-proteins (reviewed in Calo et al.,
2016). Structurally, αSYN contains an N-terminal membrane-
binding domain, a hydrophobic core centrally involved in
protein-protein aggregation, and an acidic C-terminal tail. Under
physiological conditions, αSYN is able to fold into soluble tetra-
and octameric protein structures. In LBs, αSYN misfolding
leads to cytotoxic aggregates containing insoluble αSYN of
high molecular weight species. It should be noted that recent
experimental data showed that the intermediate oligomeric
species of αSYN are toxic and most likely precede the formation
of LBs in PD (Karpinar et al., 2009; Winner et al., 2011; Peelaerts
et al., 2015).
αSYN was shown to be modified by SUMO1 and SUMO2
in cultured cells and in mammalian brain, and SUMO1 was
also found in the brain of PD patients at the periphery of LBs
co-localizing with αSYN, which raises the possibility that the
SUMO pathway plays a role in protein aggregation (Dorval
and Fraser, 2006; Kim et al., 2011; Krumova et al., 2011).
Krumova et al. (2011) engineered a transgenic His-tagged
SUMO2 mouse model and reported that sumoylation of αSYN
occurs at the lysine 96 and 102 residues. They further showed
that αSYN sumoylation reduces its propensity to aggregate
in dopaminergic neurons of a rat model of PD. However,
another study published almost simultaneously that sumoylation
of αSYN promotes αSYN aggregates formation (Oh et al.,
2011). Intriguingly, aggregates and inclusions formed as a result
of impaired proteasome activity contain the sumoylated form
of αSYN (Kim et al., 2011). Since the sumoylation of αSYN
does not affect its ubiquitination, a proteasomal dysfunction
may result in the accumulation of sumoylated αSYN and
subsequently in αSYN toxic aggregation (Kim et al., 2011).
Of note, a study that was performed in yeast confirmed
the protective role of sumoylation against αSYN aggregation
(Shahpasandzadeh et al., 2014). Moreover, this study showed
that phosphorylation of αSYN can be additionally important for
αSYN clearance through proteosomal degradation and suggested
that sumoylation could modulate the interaction of αSYN with
different kinases influencing its degradation (Shahpasandzadeh
et al., 2014). Whether there is an active interplay between
these two modifications of αSYN and whether they play a cell
protective function against PD in the mammalian brain remains
to be tested.
Interestingly, the extracellular spreading of αSYN has been
reported in PD and Kunadt et al. (2015) have recently examined
the possibility that sumoylation could serve as a regulatory
mechanism for the sorting and the extracellular vesicular
release of αSYN in neurons. They showed that sumoylation
of proteins can mediate their extracellular sorting via the
Endosomal Sorting Complex Required for Transport (ESCRT)
into the extracellular vesicle pathway. Most importantly, they
demonstrated that SUMO is recruited to ESCRT formation
sites by the interaction with phosphoinositols and that
sumoylation acts as a sorting signal for the extracellular vesicular
release of αSYN (Kunadt et al., 2015). These data provide
strong evidence for a role of the SUMO modification as a
regulator of αSYN sorting to the extracellular space, possibly
contributing to the interneuronal toxic spreading of αSYN
reported in the disease and consequently to the etiology of
PD.
Sumoylation of DJ-1
DJ-1 mutations have been linked to 1–2% of early-onset PD
cases. DJ-1 is a molecular chaperone with cytoprotective
functions under oxidative stress; in addition DJ-1 also acts
as a transcriptional regulator. The DJ-1 protein is expressed
in all brain regions, localizing to neurons and glial cells.
DJ-1 is found within the cytoplasm, the nucleus, and in
association with the mitochondria and the endoplasmic
reticulum (reviewed in Eckermann, 2013). Interestingly,
DJ-1 is present in presynaptic terminals, colocalizing with
synaptophysin and associating with synaptic vesicles and also at
the postsynapse, in dendritic spines (Usami et al., 2011) where it
is involved in synaptic neurotransmission and induction of LTD
(Wang et al., 2008).
Sumoylation of DJ-1 occurs on the lysine 130 residue and
has been shown to increase upon UV irradiation. Moreover,
this modification is necessary for DJ-1 to be in a fully activated
form (Shinbo et al., 2006). The PD-associated DJ-1 mutation
L166P leads to impaired DJ-1 sumoylation and decreases its
solubility (Shinbo et al., 2006). Interestingly, the DJ-1 K130R
mutation does not impact on the protein structure but rather
leads to multi-/polysumoylation of the DJ-1 at alternative SUMO
sites (Tao and Tong, 2003). Thus the elucidation of the exact
synaptic function of DJ-1 sumoylation and how a defect in its
sumoylation balance could impact synaptic function remains to
be determined.
Overall, these findings highlight the key roles played by the
sumoylation pathway in PD and we believe that the aim at
clarifying the involvement of the SUMO process in the etiology
of PD will become an active area of future research.
Frontiers in Synaptic Neuroscience | www.frontiersin.org 16 April 2016 | Volume 8 | Article 9
Schorova and Martin Synaptic Sumoylation
Sumoylation of Parkin
Although the loss-of-function mutations within the PARK2
gene, coding for the protein parkin, are the most common
autosomal recessive juvenile causes of PD, the responsible
molecular mechanisms remain unclear. Parkin is a RING-
domain-containing E3 Ubiquitin ligase that is widely expressed
throughout the CNS and can associate with PDZ scaffolding
proteins at the postsynaptic membrane. Notably, parkin localizes
to the majority of LBs in both familial and sporadic cases of
PD. Recent findings suggest that parkin interacts with the KAR
subunit GluK2 and regulates its neuronal function (Maraschi
et al., 2014). Loss of parkin function, in vitro and in vivo,
leads to GluK2 accumulation at the plasma membrane resulting
in potentiated KAR current and consequently in the increase
in KAR-dependent excitotoxicity presenting similar phenotype
observed in autosomal recessive juvenile PD cases (Maraschi
et al., 2014). Taking into account that GluK2 sumoylation
regulates KAR endocytosis, neuronal excitability (Martin et al.,
2007a) and synaptic plasticity (Chamberlain et al., 2012), it
would be of high interest to see whether sumoylation could
provide a rescue mechanism to down-regulate the increased
surface expression and excitotoxicity seen in mouse brains that
express the Parkin mutant causing autosomal recessive juvenile
parkinsonism.
Importantly, parkin has also been shown to interact non-
covalently with SUMO1 (Um and Chung, 2006). This interaction
increased the E3 Ubiquitin ligase activity of parkin. Furthermore,
it has been reported in this work that parkin specifically
targets the SUMO E3 ligase RanBP2 for degradation (Um and
Chung, 2006). Even though sumoylation of parkin or parkin
substrates has not been directly involved in the pathogenesis
of PD, it is reasonable to think, based on previous data, that
sumoylation may directly impact on parkin’s function and so on
the pathophysiology of PD.
Huntington’s Disease (HD)
Unlike PD, HD has a monogenic fully penetrant cause with
autosomal dominant inheritance. It belongs to the group of
polyQ disorders that arise as a consequence of an expansion
of the CAG trinucleotide repeat (encoding for glutamine) in
specific genes. In HD, the deleterious CAG expansion leads
to a polyQ expansion (≥ 40 instead of 23 glutamine residues
in the normal Htt) within the amino-terminal domain of the
Huntingtin (Htt) protein with the general agreement that longer
polyQ expansions predict earlier onsets of the disease. Clinical
hallmarks of HD are progressive motor decline leading to
severe motor dysfunction, psychiatric disturbances and cognitive
impairment. HD results from the toxic gain-of-function of
expanded polyQ in Htt and its accumulation in affected
neurons leads to neuronal cell death primarily in the striatum.
Recent prevalence studies show that one individual in 7300 is
affected in the western world (reviewed in Ross and Tabrizi,
2011).
Sumoylation of Huntingtin
Huntingtin is a large protein of 3144 amino acids (348 kDa) that
folds into a superhelical structure with a hydrophobic core and
serves as a scaffold protein. Htt is widely expressed in neurons
and localizes both to the nucleus and the cytoplasm, shuttling
between these two compartments. The cellular functions of Htt
are still not well defined. Some studies suggested its roles in
vesicular transport, regulation of gene transcription and RNA
trafficking. Htt knockdown is lethal before the embryonic day 7.5
highlighting its critical role in embryonic development (Zeitlin
et al., 1995). Htt indirectly interacts with NMDARs through
PSD95 whereas presynaptic Htt is localized to synaptic vesicles,
recycling endosomes and clathrin-coated vesicles (DiFiglia et al.,
1995; Velier et al., 1998). Htt has been shown to influence the
production and the transport of the growth factor BDNF in mice,
and in cultured neurons Htt stimulates BDNF vesicle trafficking
(Gauthier et al., 2004).
Importantly, several types of PTMs have been described for
Htt including sumoylation and ubiquitination. A pathogenic
fragment of Htt can be modified by both SUMO-1 and
ubiquitin at the same lysine residue (Steffan et al., 2004).
This group further showed that sumoylation stabilizes the
pathogenic Htt fragment and reduces its ability to form
aggregates in neuronal cell lines probably leading to a decrease
in intracellular concentration of the toxic peptide (Steffan
et al., 2004). Interestingly, genetic reduction of SUMO proteins
in a Drosophila model of HD results in neuroprotection
(Steffan et al., 2004). Moreover, potentiated sumoylation of
mutant Htt that was caused by the action of the mutant
Htt-specific SUMO E3 ligase Rhes, a striatal GTP-binding
protein, displayed increased cytotoxicity (Subramaniam et al.,
2009). Since sumoylation and ubiquitination of Htt occur on
the same lysine residue and act in an antagonistic manner,
it implies that the availability of the target lysine is critical
for the degradation of Htt by the proteasome (Steffan et al.,
2004). Because mutations that prevent these post-translational
modifications on Htt reduce the pathology in Drosophila, it is
likely that the balance between sumoylation and ubiquitination
controls both the stability and the accurate targeting of Htt
in neurons and that this tightly regulated balance is disrupted
in HD.
More recently, O’Rourke et al. (2013) reported that Htt is
sumoylated by both SUMO1 and SUMO2 primarily on the
proximal lysine 6 and 9 residues and that PIAS1 is a SUMO
E3 ligase for Htt. They further showed that genetic reduction
of dPIAS in a mutant Htt Drosophila model of HD, which
expresses mutant Htt, is protective confirming the previously
reported positive role of sumoylation in HD (Steffan et al., 2004).
The effect of Htt sumoylation by SUMO2 is the increase in the
insoluble form of Htt in HeLa cells similar to the accumulation
measured under proteasome inhibition. Importantly, this group
also reported that the accumulation could be modulated by
overexpression or acute knockdown of PIAS1 (O’Rourke et al.,
2013). This supports the central role of the SUMO process in
HD and also that a deregulated balance between sumoylation
and desumoylation of Htt could participate in the etiology
or in the aggravation of the disease. Accordingly, the authors
reported an accumulation of SUMO2-modified proteins in
insoluble fractions of HD post-mortem striata (O’Rourke et al.,
2013).
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Alzheimer’s Disease (AD)
AD is the most common neurodegenerative condition
causing severe memory deficits. AD accounts for more
than 80% of dementia cases worldwide with no cure yet
available (reviewed in Lee et al., 2013). Although the exact
causes of AD are still much discussed, the pathology is
characterized by the presence of intra- and extracellular protein
aggregates mainly composed of Tau and β-amyloid (Aβ)
proteins, which are toxic to the brain since they induce the
loss of synapses, synaptic impairments and consequently,
neuronal cell death (reviewed in Spires-Jones and Hyman,
2014).
Genetic studies have linked Single nucleotide polymorphisms
(SNPs) in genes encoding the SUMO-activating enzyme
SAE2 (Grupe et al., 2007; Corneveaux et al., 2010), the
SUMO-conjugating enzyme Ubc9 (Ahn et al., 2009) and the
desumoylase SENP3 (Weeraratna et al., 2007) to sporadic late
onset AD. Immunohistological studies also revealed stronger
SUMO immunoreactivities in hippocampal neurons of post-
mortem AD brains compared to control patients (Li et al.,
2003).
Sumoylation of Amyloid Precursor Protein (APP)
Interestingly, the APP from which Aβ is generated, and
Tau have been both proposed to be substrates of the
sumoylation machinery (reviewed in Spires-Jones and Hyman,
2014). Aβ is a small peptide of 4 kDa implicated in
synaptic physiology and plasticity. The enzymatic machinery
generating Aβ, which is composed of β- and γ-secretases, is
partly localized in synaptic compartments. Aβ can directly
bind to several synaptic receptors including NMDA and
EphB2 receptors (De Felice et al., 2007; Simón et al.,
2009). In cultured neurons the clustering of Aβ at excitatory
synapses blocks the diffusion of mGlu5 receptors leading to
increased calcium levels and hyperexcitability (Renner et al.,
2010).
To date, the investigation into the effects of the sumoylation
process in AD has generated mixed results. In 2003, the over-
expression of SUMO3 was reported to dramatically reduce the
Aβ production, whereas the expression of a SUMO3 form
bearing the K11R mutation and therefore unable to form poly-
SUMO chains displayed the opposite effect (Li et al., 2003).
An additional work in 2008 showed that sumoylation of APP
at the lysine 587 and 595 residues decreases the levels of Aβ
aggregates in HeLa cells probably by altering the availability of
the β-secretase cleavage (Zhang and Sarge, 2008). Conversely,
two separate studies showed that sumoylation increases Aβ
production independently of SUMO conjugation (Dorval et al.,
2007) or via a mechanism involving the interaction of SUMO1
with BACE1, which is known to initiate the generation of Aβ
(Yun et al., 2013). However, it should be noted that none
of these studies examined the effects of Aβ sumoylation in
neuronal cells. The authors rather used over-expression systems
that might not reflect the exact mechanisms involved in the
pathophysiology of AD. Considering the molecular complexity
of AD and the off-target effects of SUMO over-expression,
given the wide range of cellular pathway targeted by this
modification, it will be of great interest to further address these
discrepancies.
A more recent study examined the expression profile of the
members of the SUMOmachinery in the Tg2576mousemodel of
AD that over-expresses APP (Nistico et al., 2014). They reported
a significant increase in SUMO1-modified proteins and Ubc9
in the transgenic mice at 3 and 6 months of age compared to
the WT littermates. SENP1 protein levels were also increased
at the age of 3 months. On the contrary, the expression levels
of SUMO2/3-modified proteins were markedly decreased at the
age of 17 months and unchanged at the other examined stages
(Nistico et al., 2014). This study thus supported the general
belief of the field that the sumoylation/desumoylation balance
is crucial and when deregulated it may participate in disease
pathophysiology.
Sumoylation of Tau Protein
Tau is a microtubule-binding and stabilizing protein initially
discovered to localize in axons (reviewed in Spires-Jones and
Hyman, 2014). Recent data also suggest its roles in the regulation
of protein composition at the postsynaptic density (Ittner et al.,
2010). Moreover, tau was observed both in dendritic spines of
normal as well as AD post-mortem brains (Tai et al., 2012). In
AD, Tau is hyper-phosphorylated, detached from microtubules
and aggregates into tangles within the somatodendritic region.
It should be noted that not all neurons that have died display
neurofibrillary tangles, suggesting that other pathological events
must occur during the AD progression (Spires-Jones et al.,
2014). Tau can be sumoylated in different cell types, mainly
at the lysine 340 residue within a microtubule binding site
(Dorval and Fraser, 2006). Tau sumoylation was affected upon
proteasome inhibition suggesting that the lysine 340 residue is
also a target for ubiquitination and that the balance between
these two PTMs regulates Tau degradation (Dorval and Fraser,
2006). Intriguingly, the hyper-phosphorylated Tau aggregates
stain positively for SUMO1 in an APP transgenic mouse model
of AD, but not in post-mortem brain sections of AD patients
(Pountney et al., 2003; Takahashi et al., 2008). In contrast, a
recent study revealed that SUMO1 immunoreactivity colocalized
with hyper-phosphorylated Tau in the cortex and hippocampal
CA1 region of post-mortem AD brains, whereas no signal
was measured for aged-matched control brains (Luo et al.,
2014).
Sumoylation was also reported to promote Tau
phosphorylation, and conversely, the hyper-phosphorylation
of Tau induced Tau sumoylation (Luo et al., 2014). Luo et al.
(2014) further showed that Tau sumoylation at the lysine
340 residue inhibited its ubiquitination and consequently its
degradation. In addition, the exposure of cultured neurons
to Aβ increased Tau-phosphorylation and sumoylation in a
dose-dependent manner, which indicates that Aβ can act as an
upstream regulator for tau phosphorylation and sumoylation
(Luo et al., 2014). Altogether, these findings contribute to a
better understanding of the role of sumoylation in AD and
provide evidence for a putative mechanism explaining how the
pathological accumulation of hyper-phosphorylated Tau occurs
in AD brains.
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CONCLUDING REMARKS
It is nowadays very clear that the sumoylation process acts as a
major signaling pathway essential for the regulation of synaptic
function. The available set of identified sumoylated substrates
is rapidly expanding at the presynaptic site but is still quite
limited in the postsynaptic area. We are, however, confident that
the recent technical advances in the proteomic field will allow
the identification of novel SUMO target proteins and that such
neuronal and synaptic SUMOylomes will help to better assess the
central role fulfilled by sumoylation in synaptic transmission and
plasticity.
As highlighted in this review, the sumoylation process
contributes to a wide range of regulatory actions in the
developing brain, and also that disruption of the equilibrium
between the sumoylated and non-sumoylated state of
proteins is directly linked to several neurodevelopmental and
neurodegenerative diseases. Therefore, the better comprehension
of the mechanisms that regulate the spatiotemporal distribution,
targeting and activity of the sumoylation machinery in neurons
will certainly provide valuable information regarding how the
sumoylation/desumoylation balance is orchestrated in the brain
and at synapses.
We can now expect that the functional characterization
of novel SUMO regulatory pathways as well as the
discovery of additional sumoylated substrates at all
stages of the brain development will facilitate a deeper
understanding of the SUMO process in brain function
and help evaluate its potential implication in pathological
conditions.
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